Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells

PURPOSE: The usual first-line strategy of wild-type EGFR (wtEGFR) non-small cell lung cancer (NSCLC) remains cisplatin-based chemotherapy. However, cisplatin often loses effectiveness because most tumors acquire drug resistance over time. As EGFR is the most important pro-survival/proliferation sign...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Cancer Res Clin Oncol
Autors principals: Li, Amin, Cao, Weiya, Liu, Xueke, Zhang, Yinci, Ma, Yongfang, Xu, Ruyue, Zhang, Rongbo, Liu, Xinkuang, Zhou, Shuping, Wang, Ruikai, Liu, Jiachang, Tang, Xiaolong
Format: Artigo
Idioma:Inglês
Publicat: Springer Berlin Heidelberg 2020
Matèries:
Original Article – Cancer Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7185832/
https://ncbi.nlm.nih.gov/pubmed/32342201
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00432-020-03228-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars